SCHEMBL5118965

SCHEMBL5118965

CCCc1c(Cc2ccnn2-c2ncccc2C#N)ncn2nc(CC(C)C)nc12

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118983 0.92 — —
SCHEMBL5110489 0.90 KDM4E (0.30) KDM4E
SCHEMBL5105725 0.89 ALDH1A1 (0.30) ALDH1A1
SCHEMBL5108595 0.88 KDM4E (0.32) KDM4EALDH1A1GAAHPGDL3MBTL1
SCHEMBL5113311 0.88 — —
SCHEMBL5110424 0.88 — —
SCHEMBL14289584 0.88 — —
SCHEMBL5118207 0.87 PKM (0.33) KDM4EALDH1A1
SCHEMBL5119310 0.87 — —
SCHEMBL14289585 0.87 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004269-A1 Pyrazolylmethy Heteroaryl Derivatives NEUROGEN CORPORATION 2008-01-03 — — US disclosed
US-20080004269-A1 Pyrazolylmethy Heteroaryl Derivatives NEUROGEN CORPORATION 2008-01-03 — — US disclosed
US-20080004269-A1 Pyrazolylmethy Heteroaryl Derivatives NEUROGEN CORPORATION 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004269-A1 Pyrazolylmethy Heteroaryl Derivatives GABBR1, GABRR1, GABRR3 KDM4E 2740/4885ALDH1A1 1753/4885GAA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback